As of 2026-04-18, the Relative Valuation of CytomX Therapeutics Inc (CTMX) is (1.54) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.82 USD, the upside of CytomX Therapeutics Inc based on Relative Valuation is -131.9%.
The range of the Relative Valuation is (1.42) - (1.73) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.2x - 21.0x | 18.8x |
| Forward P/E multiples | 15.7x - 20.9x | 18.2x |
| Fair Price | (1.42) - (1.73) | (1.54) |
| Upside | -129.5% - -135.9% | -131.9% |
| Date | P/E |
| 2026-04-17 | -58.15 |
| 2026-04-16 | -59.00 |
| 2026-04-15 | -55.02 |
| 2026-04-14 | -54.77 |
| 2026-04-13 | -52.96 |
| 2026-04-10 | -52.96 |
| 2026-04-09 | -51.15 |
| 2026-04-08 | -51.28 |
| 2026-04-07 | -51.88 |
| 2026-04-06 | -53.08 |
| 2026-04-02 | -55.02 |
| 2026-04-01 | -55.02 |
| 2026-03-31 | -56.70 |
| 2026-03-30 | -53.21 |
| 2026-03-27 | -54.53 |
| 2026-03-26 | -53.33 |
| 2026-03-25 | -50.91 |
| 2026-03-24 | -51.15 |
| 2026-03-23 | -53.81 |
| 2026-03-20 | -53.69 |
| 2026-03-19 | -57.67 |
| 2026-03-18 | -53.08 |
| 2026-03-17 | -65.75 |
| 2026-03-16 | -81.44 |
| 2026-03-13 | -56.46 |
| 2026-03-12 | -58.76 |
| 2026-03-11 | -58.88 |
| 2026-03-10 | -58.88 |
| 2026-03-09 | -60.69 |
| 2026-03-06 | -56.46 |
| 2026-03-05 | -57.55 |
| 2026-03-04 | -61.17 |
| 2026-03-03 | -58.03 |
| 2026-03-02 | -64.43 |
| 2026-02-27 | -64.79 |
| 2026-02-26 | -66.11 |
| 2026-02-25 | -69.73 |
| 2026-02-24 | -65.63 |
| 2026-02-23 | -67.32 |
| 2026-02-20 | -65.51 |
| 2026-02-19 | -65.99 |
| 2026-02-18 | -65.27 |
| 2026-02-17 | -63.58 |
| 2026-02-13 | -64.18 |
| 2026-02-12 | -65.51 |
| 2026-02-11 | -67.08 |
| 2026-02-10 | -66.72 |
| 2026-02-09 | -68.77 |
| 2026-02-06 | -68.41 |
| 2026-02-05 | -63.22 |